Highlights of This Issue  3359

SPECIAL FEATURES

CCR Translations

3361  MET as a Target in Papillary Renal Cell Carcinoma
André P. Fay, Sabina Signoretti, and Toni K. Choueiri
See related article, p. 3411

CCR Perspectives in Drug Approval

3364  U.S. Food and Drug Administration Inspections of Clinical Investigators: Overview of Results from 1977 to 2009
Sonia K. Morgan-Linnell, David J. Stewart, and Razelle Kurzrock

Statistics in Clinical Cancer Research

3371  Blocking and Randomization to Improve Molecular Biomarker Discovery
Li-Xuan Qin, Qin Zhou, Faina Bogomolniy, Liliana Villafania, Narciso Olivera, Magali Cavatore, Jaya M. Satagopan, Colin B. Begg, and Douglas A. Levine

Molecular Pathways

3379  Molecular Pathways: CDK4 Inhibitors for Cancer Therapy
Mark A. Dickson

3384  Molecular Pathways: Niches in Metastatic Dormancy
Kenji Yumoto, Matthew R. Eber, Janice E. Berry, Russell S. Taichman, and Yusuke Shiozawa

Review

3390  Infusions of Allogeneic Natural Killer Cells as Cancer Therapy
Wing Leung

HUMAN CANCER BIOLOGY

3401  Efficient Identification of Mutated Cancer Antigens Recognized by T Cells Associated with Durable Tumor Regressions
Yong-Chen Lu, Xin Yao, Jessica S. Crystall, Yong F. Li, Mona El-Gamil, Colin Gross, Lindy Davis, Mark E. Dudley, James C. Yang, Yardena Samuels, Steven A. Rosenberg, and Paul F. Robbins

3411  MET Is a Potential Target across All Papillary Renal Cell Carcinomas: Result from a Large Molecular Study of pRCC with CGH Array and Matching Gene Expression Array
Laurence Albiges, Justine Guegan, Audrey Le Formal, Virginie Verkarre, Nathalie Rioux-Leclercq, Mathilde Sibony, Jean-Christophe Bernhard, Philippe Camparo, Zahara Merabet, Vincent Molinie, Yves Allory, Cedric Orear, Sophie Coupé, Sophie Gad, Jean-Jacques Patard, and Bernard Escudier
See related article, p. 3361

3422  Prevailing Role of Contact Guidance in Intrastromal T-cell Trapping in Human Pancreatic Cancer
Natalie Hartmann, Nathalia A. Giese, Thomas Giese, Isabel Poschke, Rienk Olfringa, Jens Werner, and Eduard Ryschick

3434  Overexpression of Sirt7 Exhibits Oncogenic Property and Serves as a Prognostic Factor in Colorectal Cancer
Hongyan Yu, Wen Ye, Jiangxue Wu, Xiangqi Meng, Ran-yi Liu, Xiaofang Ying, Yi Zhou, Hui Wang, Changchuan Pan, and Wenlin Huang

CANCER THERAPY: PRECLINICAL

3446  Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma
Mohammad Atefi, Earl Avramis, Amanda Lassen, Deborah J.L. Wong, Lidia Robert, David Foulad, Michael Cerniglia, Bjorn Titz, Thinline Chodon, Thomas G. Graeber, Begonya Comin-Anduix, and Antoni Ribas
### Table of Contents

#### LETTERS TO THE EDITOR

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>3623</td>
<td>SNPs in PI3K-PTEN-mTOR and Brain Metastases in NSCLC—Letter</td>
<td>Abolfazl Avan, Mina Maftouh, Amir Avan, Carmelo Tibaldi, Paolo A. Zucali, and Elisa Giovannetti</td>
</tr>
<tr>
<td>3625</td>
<td>SNPs in PI3K-PTEN-mTOR and Brain Metastases in NSCLC—Response</td>
<td>Qianxia Li, Huihua Xiong, and Xianglin Yuan</td>
</tr>
</tbody>
</table>

### PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>3603</td>
<td>Phase II Study of Cediranib in Patients with Advanced Gastrointestinal Stromal Tumors or Soft-Tissue Sarcoma</td>
<td>Ian Judson, Michelle Scurr, Kate Gardner, Elizabeth Barquin, Marcelo Marotti, Barbara Collins, Helen Young, Juliane M. Jürgensmeier, and Michael Leahy</td>
</tr>
<tr>
<td>3613</td>
<td>Prognostic and Therapeutic Implications of Aromatase Expression in Lung Adenocarcinomas with EGFR Mutations</td>
<td>Mikihiro Kohno, Tatsuro Okamoto, Kenichi Suda, Mototsugu Shimokawa, Hirokazu Kitahara, Shinichiro Shimamatsu, Hideyuki Konishi, Tsukihisa Yoshida, Mitsuhiro Takenoya, Tokujirō Yano, and Yoshihiko Maehara</td>
</tr>
</tbody>
</table>

#### ABOUT THE COVER

Loss of S6 phosphorylation as a biomarker of response to PI3K/mTOR pathway inhibition. The representative image shows immunohistochemical staining for phosphorylated S6 protein (ser235-236) in SUM190 breast cancer cell line xenografts treated with the pan-PI3K inhibitor BKM120. For details, see the article by O'Brien and colleagues on page 3507 of this issue.
# Clinical Cancer Research

20 (13)

*Clin Cancer Res* 2014;20:3359-3626.

<table>
<thead>
<tr>
<th>Updated version</th>
<th>Access the most recent version of this article at: <a href="http://clincancerres.aacrjournals.org/content/20/13">http://clincancerres.aacrjournals.org/content/20/13</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>E-mail alerts</td>
<td>Sign up to receive free email-alerts related to this article or journal.</td>
</tr>
<tr>
<td>Reprints and Subscriptions</td>
<td>To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at <a href="mailto:pubs@aacr.org">pubs@aacr.org</a>.</td>
</tr>
<tr>
<td>Permissions</td>
<td>To request permission to re-use all or part of this article, contact the AACR Publications Department at <a href="mailto:permissions@aacr.org">permissions@aacr.org</a>.</td>
</tr>
</tbody>
</table>